


KB-5492 free base

| | | | |
|--------------------|---|-------|----------|
| Cat. No.: | HY-47228 | | |
| CAS No.: | 113594-64-2 | | |
| Molecular Formula: | C ₂₃ H ₃₀ N ₂ O ₆ | | |
| Molecular Weight: | 430.49 | | |
| Target: | Sigma Receptor | | |
| Pathway: | Neuronal Signaling | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (232.29 mM; Need ultrasonic)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.3229 mL | 11.6147 mL | 23.2293 mL |
| | 5 mM | 0.4646 mL | 2.3229 mL | 4.6459 mL |
| | 10 mM | 0.2323 mL | 1.1615 mL | 2.3229 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

KB-5492 free base is a potent and selective inhibitor of sigma receptor, inhibits specific [³H]1,3-di(2-tolyl)guanidine (DTG) binding to the sigma receptor with an IC₅₀ of 3.15 μM. KB-5492 free base is an anti-ulcer agent^{[1][2]}.

IC₅₀ & Target

IC₅₀: 3.15 μM (sigma receptor)^[1]

In Vitro

KB-5492 (0.001-100 μM) free base inhibits specific [³H]DTG binding in a concentration-dependent manner^[1].
 KB-5492 (0.1-1 mM) free base significantly and concentration-dependently prevents the ethanol- and acidified aspirin-induced increases in ⁵¹Cr release from gastric epithelial cells^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

KB-5492 (200 mg/kg; p.o.) free base prevents macroscopic lesions in the gastric mucosa^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---------------|---|
| Animal Model: | Male Sprague-Dawley rats weighing 210-240 g are induced gastric mucosal damage ^[2] |
|---------------|---|

| | |
|-----------------|--|
| Dosage: | 200 mg/kg |
| Administration: | Oral gavage |
| Result: | Reduced the lesion length as compared with the control. Prevented the deep mucosal lesions and exfoliation of surface epithelial cells. |

REFERENCES

- [1]. Harada Y, et, al. Receptor binding profiles of KB-5492, a novel anti-ulcer agent, at sigma receptors in guinea-pig brain. *Eur J Pharmacol.* 1994 May 2; 256(3): 321-8.
- [2]. Morimoto Y, et, al. Effects of KB-5492, a new anti-ulcer agent, on ethanol- and acidified aspirin-induced gastric mucosal damage in vivo and in vitro. *Jpn J Pharmacol.* 1994 Jan; 64(1): 41-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA